VC intake was not significantly different between the two groups. Nonetheless, the mean plasma VC level was lower in the cancer group. The cancer group with VC deficiency showed a nonsignificant tendency toward higher mortality. Progression-free survival did not vary based on the presence of VC deficiency. Additionally, patients with BRAF and KRAS mutations did not exhibit significant differences in VC levels. Here, KRAS is linked to cancer.